AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth
MWN-AI** Summary
AIM ImmunoTech Inc. (NYSE American: AIM) announced on September 22, 2025, that a new peer-reviewed article published in the Journal for ImmunoTherapy of Cancer (JITC) provides compelling evidence of the beneficial effects of the company’s lead drug, Ampligen, in conjunction with interferon-alpha, on tumor growth and patient survival. The research emphasizes the role of systemic chemokine modulation in overcoming the PD-1 resistance found in "cold" tumors, indicating that enhancing the accumulation of intratumoral cytotoxic T-lymphocytes is crucial for improving the efficacy of immune checkpoint inhibitors.
The publication titled “Synergy between TLR3-ligand and IFN-? in the transient sensitization of ‘Cold’ tumors to PD-1 blockade and the induction of systemic immunity” details findings that suggest a significant potential for tumor microenvironment reprogramming strategies to enhance therapeutic outcomes in cancer treatment.
AIM ImmunoTech is dedicated to developing innovative therapies for various conditions, focusing on cancers, immune disorders, and viral diseases. Ampligen, a pioneering investigational drug that acts as a double-stranded RNA and selective TLR3 agonist, has demonstrated broad-spectrum activity in ongoing clinical trials targeting significant health challenges.
In light of these developments, the company highlights the importance of understanding the risks and uncertainties associated with forward-looking statements, particularly those related to the therapeutic approval process for Ampligen. They urge investors to consider potential risk factors as outlined in their most recent SEC filings. While the findings are promising, AIM maintains caution regarding the unpredictable nature of clinical success.
For further details, AIM ImmunoTech encourages stakeholders to visit their official website and connect through social media platforms.
MWN-AI** Analysis
AIM ImmunoTech Inc. (NYSE American: AIM) has made significant strides with the recent publication of its peer-reviewed article in the Journal for ImmunoTherapy of Cancer. The findings suggest a promising synergistic effect between Ampligen and interferon-alpha, highlighting the potential to enhance treatment outcomes for "cold" tumors resistant to PD-1 inhibitors. This positions AIM as a front-runner in immunotherapy, particularly for oncology applications.
From an investment perspective, this development could serve as a pivotal moment for AIM. The opportunity to address unmet needs in cancer treatment through innovative approaches can generate substantial interest from both institutional and retail investors. The publication underscores the scientific credibility of Ampligen, which may lead to increased confidence in the company's ongoing clinical trials and future experimental designs.
However, while the data is promising, investors should remain cautious and critically assess the inherent risks. The press release includes forward-looking statements that carry uncertainties related to regulatory approval and market adoption. AIM's ability to navigate through these risks hinges on securing positive clinical trial results and successful regulatory interactions.
In light of recent developments, investors may want to consider adopting a balanced approach: maintaining a core holding in AIM to capitalize on long-term growth opportunities while employing risk management strategies. Monitoring key milestones, such as clinical trial updates and regulatory filings, will be essential to gauge AIM’s progress.
In essence, AIM ImmunoTech presents an intriguing candidate in the biotech sector, specifically in the immunotherapy niche. However, potential investors are urged to conduct thorough due diligence and take note of the risks highlighted by the company’s disclosures before making investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
OCALA, Fla., Sept. 22, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Journal for ImmunoTherapy of Cancer ( JITC ) has published a new peer-reviewed article providing evidence of a positive combination effect of AIM’s drug Ampligen and interferon-alpha on tumor growth and subsequent subject survival.
The paper concluded that the ability of systemic chemokine modulation to eliminate the PD-1-resistance of cold tumors indicates that intratumoral cytotoxic t-lymphocyte accumulation, rather than tumor immunogenicity, is the key factor limiting the therapeutic effectiveness of immune checkpoint inhibitors. These data suggest a broad therapeutic potential of tumor microenvironment reprogramming strategies.
The article, titled " Synergy between TLR3-ligand and IFN-? in the transient sensitization of ‘Cold’ tumors to PD-1 blockade and the induction of systemic immunity ," was published in JITC on September 18.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen ® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X , LinkedIn , and Facebook .
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy for any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Investor Contact:
JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com
FAQ**
How does AIM ImmunoTech Inc. AIM plan to leverage the findings from the recent JITC publication to advance the clinical development of Ampligen in combination with interferon-alpha for 'cold' tumors?
2. What specific risks does AIM ImmunoTech Inc. AIM identify regarding the approval process for Ampligen, and how are these addressed in their strategic planning?
3. Considering the recent positive data, what are AIM ImmunoTech Inc. AIM's next steps in terms of regulatory submissions or further clinical trials for Ampligen?
4. How does AIM ImmunoTech Inc. AIM intend to educate investors on the implications of this new research on their long-term growth strategy within the immuno-oncology sector?
**MWN-AI FAQ is based on asking OpenAI questions about AIM ImmunoTech Inc. (NYSE: AIM).
NASDAQ: AIM
AIM Trading
65.82% G/L:
$0.425 Last:
435,285,985 Volume:
$0.2756 Open:
